🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Panzyga 100 mg/ml Infusionslösung, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Maze Therapeutics

    Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.

    phase 3 small molecule active

    1 trial

  2. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Lacuna Pharma Pty Ltd

    Acute pain

    phase 3 small molecule active

    1 trial

  3. Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection

    Amgen

    Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis

    phase 3 small molecule active

    1 trial

  4. Part A: Upamostat 200 mg

    RedHill Biopharma

    Covid19

    phase 3 small molecule terminated

    1 trial

  5. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Biotech Pharmaceutical Co.,

    Influenza

    phase 3 mab active

    1 trial

  6. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  7. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  8. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  9. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  10. Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  11. Peer HIV Education Program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    1 trial

  12. Peer Mentoring Intervention for HCV-Infected IDUs

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    phase 3 other completed

    1 trial

  13. Peficitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatoid Arthritis (RA)

    phase 3 small molecule completed

    1 trial

  14. Peg interferon alpha-2b

    Universal Integrated

    Hepatitis C

    phase 3 small molecule terminated

    1 trial

  15. PegIntron (peginterferon alfa-2b)

    Universal Integrated

    Hepatitis C, Chronic

    phase 3 mab terminated

    1 trial

  16. Pegcetacoplan

    Apellis Europe B.V.

    PNH

    phase 3 small molecule active

    2 trials

  17. Pegcetacoplan

    Apellis Europe B.V.

    C3G

    phase 3 small molecule active

    3 trials

  18. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  19. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  20. Pegtibatinase

    Travere Therapeutics

    Homocystinuria

    phase 3 small molecule active

    3 trials

  21. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  22. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial

  23. Pegvaliase

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule active

    2 trials

  24. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources